George Adi Mor
Known title: Chief Scientific OfficerCIK: 0001851069
George Adi Mor's purchase track record
George Adi Mor has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/29/2026 | CMMB | $20K | +35.0% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CMMB | ▲ Buy | Open Market | 4,878 | $10K | 5/29/2026 | View on chart |
| CMMB | ▲ Buy | Open Market | 4,926 | $10K | 5/29/2026 | View on chart |
| CMMB | ▼ Sell | Other | 31,712 | — | 5/29/2026 | View on chart |
| CMMB | ▼ Sell | Other | 18,750 | — | 5/29/2026 | View on chart |
| CMMB | ▼ Sell | Open Market | 7,700 | $39K | 1/3/2023 | View on chart |
| CMMB | ▼ Sell | Open Market | 6,100 | $31K | 1/3/2023 | View on chart |
| CMMB | ▼ Sell | Open Market | 324,775 | $677K | 11/16/2022 | View on chart |
| CMMB | ▼ Sell | Open Market | 257,248 | $536K | 11/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Chemomab Amends Merger Agreement for U.S. Redomiciliation
Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.
Chemomab Amends Merger Agreement for U.S. Redomiciliation. Chemomab has amended its merger agreement to facilitate a U.S. redomiciliation and combination with Scipher. This corporate restructuring is a significant development for the company's structure. The stock is currently trading near its 52-week low, reflecting the ongoing uncertainty surrounding these changes.